12/6/2023 0 Comments Stem cell biotech stockThe opinions expressed in this article are those of the writer, subject to the Publishing Guidelines. On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The firm also believes ACAD’s Phase 3 trial for “pimavanserin in negative schizophrenia has a high likelihood of reading out positive data in Q124,” as noted by Seeking Alpha. Better, it has a strong pipeline of candidates for Prader-Willi syndrome - a genetic disorder that can lead to obesity and intellectual disability - Alzheimer’s disease psychosis and issues having to do with schizophrenia.Įven better, analysts at Mizuho (NYSE: MFG) just upgraded ACAD to a Buy, with a price target of $35 - all thanks to the company’s Daybue oral therapy for the treatment of Rett syndrome. Not only does the company have two FDA-approved drugs on the market for Parkinson’s disease psychosis and Rett syndrome, but it also has a dominant position with treatments for neurological issues. ( OCUP) Ocuphire Pharma's Nyxol Eye Drops, proposed for the reversal of pharmacologically-induced mydriasis, (dilation of the pupil), is under FDA review, with a decision expected on September 28, 2023. BCLI closed Wednesday's trading at 1.68, down 4. Biotech Stocks to Buy: CRISPR Therapeutics (CRSP) The FDA's final decision on NurOwn is expected by December 8, 2023. Delving into Stem Cell Science, Nutrition. “We expect M&A and market consolidation rates to increase in the short to medium term as pharmaceutical companies turn to acquisitions to maintain a constant revenue stream and protect against the upcoming patent cliff.”Īgain, that’s great news for these top biotech stocks to buy, including these three. Find the latest Stemtech Corporation (STEK) stock quote, history, news and other vital information to help you with your stock trading and investing. In fact, according to Genetic Engineering & Biotechnology News, “a significant number of blockbuster drugs are losing their exclusivity in the next five years, and we expect that generic and biosimilar competition will be particularly fierce and intense due to cost-containment pressures,” reported Fitch Solutions. Plus, with industry heavyweights nearing patent expirations, many are on the hunt for fresh new ideas - great news for biotech stocks to buy with strong pipelines. Recession-proof, the sector is still thriving with millions of retiring baby boomers, mergers and acquisitions, new innovation, the introduction of artificial intelligence with drug discovery and demand for new treatments. InvestorPlace - Stock Market News, Stock Advice & Trading Tipsīiotech is still one of the most exciting sectors on the market.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |